Host genomic DNA integration site (IS)

Host genomic DNA integration sites are the specific chromosomal locations where exogenous genetic material, such as viral DNA or gene therapy vectors, is permanently inserted into the host genome. This process is mediated by enzymes like integrase (in retroviruses) or through DNA repair mechanisms, and it plays a pivotal role in the pathogenesis of chronic viral infections like HIV and HBV (Bushman, 2020). In clinical gene therapy, the distribution of these sites is a primary safety concern because integration near proto-oncogenes can lead to insertional mutagenesis and the development of leukemia or other malignancies (Cavazzana-Calvo et al., 2010). Consequently, monitoring integration sites using high-throughput sequencing is a standard regulatory requirement for assessing the long-term safety and clonal stability of engineered cell therapies (Biasco et al., 2012). While the sites themselves are not traditional drug targets, they represent the critical endpoint that integrase inhibitors aim to prevent in viral infections (Delelis et al., 2008). Understanding the preference of different vectors for specific genomic features, such as transcription start sites or gene bodies, is essential for designing safer genetic medicines (Schmidt et al., 2007). These sites also serve as markers for viral reservoirs in patients undergoing antiretroviral therapy, complicating efforts to achieve a functional cure for HIV (Cohn et al., 2015).

Other names

Viral integration siteProviral insertion siteVector integration siteGenomic landing padIntegration locus

Inhibition of viral integrase to prevent integration into host DNA; or the use of viral vectors to deliver genetic material into host chromosomal DNA.